Our Pricing

Ozempic vs Mounjaro Safety: Side Effects Compared

Published on: June 03, 2026

Understanding ozempic vs mounjaro side effects uk is essential when choosing between these two weight loss treatments. Both medications are GLP-1 receptor agonists licensed by the MHRA, but they differ in mechanism, side effect profiles, and overall tolerability based on extensive clinical trial data.

Understanding Ozempic vs Mounjaro Side Effects UK: Key Differences

Ozempic (semaglutide) and Mounjaro (tirzepatide) share similar gastrointestinal side effects due to their GLP-1 activity, but important differences exist. Mounjaro is a dual GIP/GLP-1 receptor agonist, whilst Ozempic targets only the GLP-1 pathway [1]. This dual mechanism may influence both efficacy and tolerability.

In the SURPASS-2 head-to-head trial comparing tirzepatide directly against semaglutide 1mg, both medications showed comparable rates of nausea (17-22% for tirzepatide vs 18% for semaglutide), but tirzepatide demonstrated slightly higher rates of diarrhoea and vomiting at the highest doses [1]. However, discontinuation rates due to adverse events were similar between treatments, ranging from 4.3% to 7.1% across tirzepatide doses versus 3.6% for semaglutide.

Most side effects with both medications occur during dose escalation and typically diminish over time as the body adapts. UK prescribers carefully titrate doses over several weeks to minimise these effects whilst optimising therapeutic benefit [2].

Common Side Effects: Mounjaro vs Ozempic Safety Comparison

Both tirzepatide and semaglutide primarily affect the gastrointestinal system. The most frequently reported side effects include nausea, diarrhoea, vomiting, constipation, and decreased appetite. These effects are directly related to how GLP-1 receptor agonists slow gastric emptying and influence satiety signals [1][3].

Clinical trial data shows nausea affects approximately 18-22% of patients on either medication, typically peaking during the first 8-12 weeks of treatment. Diarrhoea occurs in 15-20% of patients, whilst vomiting affects 8-12%. With both medications, these effects are generally mild to moderate and resolve without intervention as treatment continues [1][2].

Less common side effects shared by both treatments include injection site reactions (redness, itching, or swelling), fatigue, headache, and dyspepsia. Serious adverse events are rare with both medications but include potential risks of pancreatitis, gallbladder disease, and hypoglycaemia when combined with certain diabetes medications [3].

Managing Gastrointestinal Side Effects

UK clinical experience shows that starting with smaller meals, avoiding high-fat foods, and staying well-hydrated can significantly reduce gastrointestinal discomfort with both medications. Your prescriber may adjust your dose escalation schedule if side effects become problematic, allowing your body more time to adapt before increasing the dose.

Serious Side Effects: Which Is Safer Mounjaro or Ozempic?

Both medications carry similar warnings for serious but rare adverse events. The MHRA requires both Ozempic and Mounjaro to include warnings about potential thyroid C-cell tumours based on rodent studies, though no causal relationship has been established in humans [3]. Both are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Pancreatitis has been reported with both semaglutide and tirzepatide, occurring in less than 1% of patients in clinical trials. Symptoms include severe abdominal pain radiating to the back, and patients should discontinue treatment immediately if pancreatitis is suspected [1][3]. Gallbladder problems, including cholelithiasis and cholecystitis, have also been observed with both medications, likely related to rapid weight loss rather than the drugs themselves.

Hypoglycaemia risk is low when either medication is used alone, but increases when combined with insulin or sulfonylureas. In the SURPASS-2 trial, severe hypoglycaemia was rare with tirzepatide monotherapy (less than 0.1%), similar to semaglutide [1]. UK prescribers carefully review concurrent medications during assessment to minimise this risk.

Cardiovascular Safety Profile

Semaglutide has demonstrated cardiovascular benefits in the STEP trials, with reductions in major adverse cardiovascular events in high-risk patients [2]. Tirzepatide's cardiovascular outcome data is still emerging, though early signals from the SURPASS trials suggest a favourable safety profile. Both medications have shown improvements in cardiovascular risk factors including blood pressure and lipid profiles [1][4].

Tirzepatide vs Semaglutide Side Effects: Clinical Trial Data

The SURPASS-2 trial provides the most direct comparison of tirzepatide versus semaglutide safety. In this 40-week study of 1,879 adults with type 2 diabetes, tirzepatide at 5mg, 10mg, and 15mg doses was compared against semaglutide 1mg [1]. Treatment-emergent adverse events occurred in 81-86% of tirzepatide patients versus 81% of semaglutide patients, with most events being mild to moderate.

Gastrointestinal adverse events were the primary reason for discontinuation across all groups. Nausea rates were 17%, 19%, and 22% for tirzepatide 5mg, 10mg, and 15mg respectively, compared to 18% for semaglutide. Diarrhoea was slightly more common with tirzepatide (16-18%) than semaglutide (12%), whilst vomiting ranged from 8-10% across tirzepatide doses versus 8% for semaglutide [1].

The STEP programme trials for semaglutide in obesity showed similar tolerability patterns. In STEP 1, which studied semaglutide 2.4mg for weight management, gastrointestinal disorders were reported in 74% of semaglutide patients versus 48% of placebo patients, with most events being transient and mild to moderate [2]. This higher dose used for weight loss may produce slightly more gastrointestinal effects than the 1mg dose used in diabetes treatment.

Mounjaro Safety Profile UK: What Patients Experience

Real-world UK experience with Mounjaro since its 2023 launch aligns closely with clinical trial data. Most patients tolerate the medication well when dose escalation follows the recommended schedule: starting at 2.5mg weekly for four weeks, then increasing to 5mg, with further increases to 7.5mg, 10mg, 12.5mg, or 15mg based on individual response and tolerability [1].

At Cured Pharmacy, our clinical team finds that patients who experience significant nausea or vomiting often benefit from remaining at their current dose for an additional month before escalating. This personalised approach, combined with dietary modifications and proper injection technique, helps optimise tolerability whilst maintaining therapeutic benefit.

Mounjaro is available at Cured Pharmacy from £124.99, with all doses requiring clinical assessment by a UK prescriber. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team provide ongoing support to help patients manage any side effects and achieve their weight management goals safely.

Long-Term Safety Considerations

Both medications have been studied for up to 72 weeks in clinical trials, demonstrating sustained tolerability over extended treatment periods [1][2]. Most gastrointestinal side effects peak during the first 20 weeks and decline thereafter. Long-term safety monitoring continues as these medications are used more widely in clinical practice, with UK prescribers reviewing patients regularly to assess ongoing suitability.

Choosing Between Ozempic and Mounjaro: Safety Factors to Consider

When comparing ozempic mounjaro comparison uk safety profiles, both medications demonstrate similar overall tolerability with comparable discontinuation rates. The choice between them often depends on individual factors including treatment goals, previous medication experience, concurrent health conditions, and cost considerations rather than safety differences alone.

Patients with a history of gastrointestinal conditions may require closer monitoring with either medication. Those taking medications that affect blood sugar should be carefully assessed for hypoglycaemia risk. Both treatments are contraindicated in pregnancy, and women of childbearing potential should use effective contraception [3][4].

Your UK prescriber will consider your complete medical history, current medications, and personal circumstances when recommending the most appropriate treatment. At Cured Pharmacy, our online consultation takes under three minutes and ensures a thorough clinical assessment by UK-registered prescribers before any medication is dispensed. Alternative treatments including Wegovy and Saxenda are also available, each with distinct safety profiles that may suit different patients.

When to Contact Your Prescriber

Seek immediate medical attention if you experience severe abdominal pain that doesn't resolve, persistent vomiting preventing fluid intake, signs of allergic reaction (rash, swelling, difficulty breathing), or symptoms of pancreatitis. Contact your prescriber if side effects are significantly affecting your quality of life or if you have concerns about continuing treatment. Most side effects can be managed through dose adjustments or supportive measures without discontinuing treatment entirely.

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Summary of Product Characteristics: Mounjaro 2.5 mg solution for injection in pre-filled pen. MHRA. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.